These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 16250662)

  • 1. Synthesis of 5-nitro-2-furancarbohydrazides and their cis-diamminedichloroplatinum complexes as bitopic and irreversible human thioredoxin reductase inhibitors.
    Millet R; Urig S; Jacob J; Amtmann E; Moulinoux JP; Gromer S; Becker K; Davioud-Charvet E
    J Med Chem; 2005 Nov; 48(22):7024-39. PubMed ID: 16250662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and evaluation of curcumin analogues as potential thioredoxin reductase inhibitors.
    Qiu X; Liu Z; Shao WY; Liu X; Jing DP; Yu YJ; An LK; Huang SL; Bu XZ; Huang ZS; Gu LQ
    Bioorg Med Chem; 2008 Sep; 16(17):8035-41. PubMed ID: 18678491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds.
    Witte AB; Anestål K; Jerremalm E; Ehrsson H; Arnér ES
    Free Radic Biol Med; 2005 Sep; 39(5):696-703. PubMed ID: 16085187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological activity of prodrug inhibitors of the thioredoxin-thioredoxin reductase system.
    Wipf P; Lynch SM; Powis G; Birmingham A; Englund EE
    Org Biomol Chem; 2005 Nov; 3(21):3880-2. PubMed ID: 16240002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diaryl chalcogenides as selective inhibitors of thioredoxin reductase and potential antitumor agents.
    Engman L; Cotgreave I; Angulo M; Taylor CW; Paine-Murrieta GD; Powis G
    Anticancer Res; 1997; 17(6D):4599-605. PubMed ID: 9494575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benzimidazol-2-ylidene gold(I) complexes are thioredoxin reductase inhibitors with multiple antitumor properties.
    Rubbiani R; Kitanovic I; Alborzinia H; Can S; Kitanovic A; Onambele LA; Stefanopoulou M; Geldmacher Y; Sheldrick WS; Wolber G; Prokop A; Wölfl S; Ott I
    J Med Chem; 2010 Dec; 53(24):8608-18. PubMed ID: 21082862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatinum and transplatinum complexes with benzyliminoether ligands; synthesis, characterization, structure-activity relationships, and in vitro and in vivo antitumor efficacy.
    Sbovata SM; Bettio F; Mozzon M; Bertani R; Venzo A; Benetollo F; Michelin RA; Gandin V; Marzano C
    J Med Chem; 2007 Sep; 50(19):4775-84. PubMed ID: 17713897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell line-directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs.
    Kunkel MW; Kirkpatrick DL; Johnson JI; Powis G
    Anticancer Drug Des; 1997 Dec; 12(8):659-70. PubMed ID: 9448705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of both thioredoxin reductase and glutathione reductase may contribute to the anticancer mechanism of TH-302.
    Li S; Zhang J; Li J; Chen D; Matteucci M; Curd J; Duan JX
    Biol Trace Elem Res; 2010 Sep; 136(3):294-301. PubMed ID: 19838642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platinum complexes can inhibit matrix metalloproteinase activity: platinum-diethyl[(methylsulfinyl)methyl]phosphonate complexes as inhibitors of matrix metalloproteinases 2, 3, 9, and 12.
    Sasanelli R; Boccarelli A; Giordano D; Laforgia M; Arnesano F; Natile G; Cardellicchio C; Capozzi MA; Coluccia M
    J Med Chem; 2007 Jul; 50(15):3434-41. PubMed ID: 17583333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclodextrin-derived diorganyl tellurides as glutathione peroxidase mimics and inhibitors of thioredoxin reductase and cancer cell growth.
    McNaughton M; Engman L; Birmingham A; Powis G; Cotgreave IA
    J Med Chem; 2004 Jan; 47(1):233-9. PubMed ID: 14695837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and in vitro antitumor activity of platinum acetonimine complexes.
    Boccarelli A; Intini FP; Sasanelli R; Sivo MF; Coluccia M; Natile G
    J Med Chem; 2006 Jan; 49(2):829-37. PubMed ID: 16420068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and characterization of platinum(II) oxadiazoline complexes and their in vitro antitumor activity in platinum-sensitive and -resistant cancer cell lines.
    Coley HM; Sarju J; Wagner G
    J Med Chem; 2008 Jan; 51(1):135-41. PubMed ID: 18072719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural product based inhibitors of the thioredoxin-thioredoxin reductase system.
    Wipf P; Lynch SM; Birmingham A; Tamayo G; Jiménez A; Campos N; Powis G
    Org Biomol Chem; 2004 Jun; 2(11):1651-8. PubMed ID: 15162219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and structure-activity relationship of novel antitumoral platinum xanthate complexes.
    Friebolin W; Schilling G; Zöller M; Amtmann E
    J Med Chem; 2004 Apr; 47(9):2256-63. PubMed ID: 15084124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and anticancer activity of [2-hydroxy-1,3-diaminopropane-kappa 2N,N'] platinum(II) complexes.
    Liu W; Chen X; Xie M; Lou L; Ye Q; Yu Y; Hou S
    J Inorg Biochem; 2008 Oct; 102(10):1942-6. PubMed ID: 18707762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parallel syntheses of disulfide inhibitors of the thioredoxin redox system as potential antitumor agents.
    Kirkpatrick DL; Watson S; Kunkel M; Fletcher S; Ulhaq S; Powis G
    Anticancer Drug Des; 1999 Oct; 14(5):421-32. PubMed ID: 10766297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, cytotoxicity and DNA-binding levels of ammine/propylamine platinum(II) complexes with carboxylates.
    Zhang J; Zhao X
    Eur J Med Chem; 2007 Feb; 42(2):286-91. PubMed ID: 17084487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondria-targeted chemotherapeutics: the rational design of gold(I) N-heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to thiols.
    Hickey JL; Ruhayel RA; Barnard PJ; Baker MV; Berners-Price SJ; Filipovska A
    J Am Chem Soc; 2008 Sep; 130(38):12570-1. PubMed ID: 18729360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sterically hindered complexes of platinum(II) with planar heterocyclic nitrogen donors. A novel complex with 1-methyl-cytosine has a spectrum of activity different from cisplatin and is able of overcoming acquired cisplatin resistance.
    Margiotta N; Natile G; Capitelli F; Fanizzi FP; Boccarelli A; De Rinaldis P; Giordano D; Coluccia M
    J Inorg Biochem; 2006 Nov; 100(11):1849-57. PubMed ID: 16959321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.